Assessment of musculoskeletal toxicity 5 Years after therapy with levofloxacin

Pediatrics

Volumn 134, Issue 1, 2014, Pages

  Bradley, John S ^a   Kauffman, Ralph E ^b   Balis, Dainius A ^c   Duffy, Ciaran M ^d   Gerbino, Peter G ^e   Maldonado, Samuel D ^c   Noel, Gary J ^c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e Montage Cardiology   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Articular growth and development; Cartilage; Fluoroquinolone toxicity; Levofloxacin

Indexed keywords

LEVOFLOXACIN;

ADOLESCENT; ADVERSE OUTCOME; ARTICLE; CARTILAGE INJURY; CHILD; CHILD GROWTH; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ARTICULAR/GROWTH AND DEVELOPMENT; CARTILAGE; FLUOROQUINOLONE TOXICITY; LEVOFLOXACIN;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CARTILAGE DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEVOFLOXACIN; MALE; MUSCULOSKELETAL DISEASES; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84904167188     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3636     Document Type: Article

References (20)

1. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25(5):1196-1204 (Pubitemid 27513209)
2. 62nd Meeting of the Food and Drug Administration Anti-Infective Drugs Advisory Committee; November 19, 1997; Bethesda, MD
3. Sáez-Llorens X, McCoig C, Feris JM, et al; Trovan meningitis Study Group. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J. 2002;21(1):14-22 (Pubitemid 34073952)
4. Sher L, Arguedas A, Husseman M, et al. Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. Pediatr Infect Dis J. 2005;24(4):301-308 (Pubitemid 40525336)
5. Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis. 2005;41(4):470-478 (Pubitemid 41099638)
6. Sáez-Llorens X, Rodriguez A, Arguedas A, et al. Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. Pediatr Infect Dis J. 2005;24(4):293-300 (Pubitemid 40525335)
7. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J. 2003;22(11):943-949 (Pubitemid 37445069)
8. Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2008;27(6):483-489
9. Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2006;25(12):1102-1109 (Pubitemid 44900672)
10. Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007;26(10):868-878 (Pubitemid 47494158)
11. Division of Anti-Infective Drug Products HFD-520. Review and evaluation of pharmacology and toxicology data. Available at: www.accessdata.fda.gov/ drugsatfda-docs/nda/96/020634-3.pdf. Accessed January 5, 2013
12. Levaquin package insert. Available at: http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm?setid=a1f01e8e-97e9-11de-b91d-553856d89593. Accessed January 5, 2013
13. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10):879-891 (Pubitemid 47494159)
14. Patterson DR. Quinolone toxicity: methods of assessment. Am J Med. 1991;91(6A):35S-37S
15. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009;33(3):194-200
16. von Keutz E, Rühl-Fehlert C, Drommer W, Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004;78(7):418-424 (Pubitemid 39062235)
17. Riecke K, Lozo E. ShakiBaei M, et al. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada
18. Ciprofloxacin package insert. Available at: http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm?setid=457d7810-23f1-4318-9561-2cd58a9cf973. Accessed March 8, 2014
19. Echols R, Hamed K, Arguedas A, et al. Gatifloxacin therapy for children: turn on the light. Clin Infect Dis. 2005;41(12):1824-1825 (Pubitemid 41759875)
20. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128(4). Available at: www.pediatrics.org/cgi/content/full/128/ 4/e1034